Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Investigational PD-L1–targeted immunotherapy safe for patients with triple...

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant...

Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA )

Pembrolizumab promising for lung cancer, clinical outcomes correlate with...

Dr Edward Garon - David Geffen School of Medicine at the University of...

Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial ( Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK

BRAF 'behind the scenes' in melanoma: A scientific story of discovery ( Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK )

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for...

Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice ( Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium )

Response and resistance with BRAF inhibitors: Mechanisms, markers and...

Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA

Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions ( Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA )

DNA repair inhibitors to overcome drug resistance

Dr Ruth Plummer - Newcastle University, Newcastle, UK

DNA repair inhibitors to overcome drug resistance ( Dr Ruth Plummer - Newcastle University, Newcastle, UK )

Developments in immunotherapy

Prof Lillian Siu - University Health Network, Toronto, Canada

Developments in immunotherapy ( Prof Lillian Siu - University Health Network, Toronto, Canada )

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Drugging the cancer genome to overcome drug resistance

Prof Paul Workman - Institute of Cancer Research, UK

Drugging the cancer genome to overcome drug resistance ( Prof Paul Workman - Institute of Cancer Research, UK )

More from ecancer